Time course of selected treatment emergent adverse events (TEAEs) in NAPOLI-1: a phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy.
Authors
Hubner, Richard AChen, L
Siveke, J
Li, C
Bodoky, G
Dean, A
Shan, Y
Jameson, G
Macarulla, T
Lee, K
Cunningham, D
Blanc, J
Chiu, C
Schwartsmann, G
Braiteh, F
Mamlouk, K
Belanger, B
de Jong, F
von Hoff, D
Wang-Gillam, A
Affiliation
Department of Medical Oncology, Christie NHS Foundation Trust, ManchesterIssue Date
2016-10-01
Metadata
Show full item recordCitation
Time course of selected treatment emergent adverse events (TEAEs) in NAPOLI-1: a phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy. 2016, 27(suppl 6):693P Annals of OncologyJournal
Annals of OncologyDOI
10.1093/annonc/mdw371.85Additional Links
https://academic.oup.com/annonc/article/2799440/TimeType
Meetings and ProceedingsLanguage
enISSN
0923-75341569-8041
ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdw371.85